Question 1

Is the researcher pool public, private/invite-only, or does the platform support both models, and how are researchers vetted before being invited to a private program (background checks, skill verification, past performance)?

Accepted Answer

Look for a clear vetting methodology for private programs (not just self-reported researcher claims) and be explicit about the public/private tradeoff: broader coverage versus more controlled, lower-noise engagement.

Question 2

Describe the triage process for incoming submissions — is initial triage (validity check, deduplication, severity assessment) performed by the platform's own security team before reaching the customer, and what is the average time from submission to a customer-actionable triaged report with a customer reference?

Accepted Answer

Platform-side triage that filters noise/duplicates before reaching the customer materially reduces internal team burden; ask for a real average triage-time figure from production use, not a marketed SLA that may not reflect actual performance.

Question 3

What is the payout/reward management process — does the platform handle researcher payments directly (currency conversion, tax forms, payment methods), or does the customer need to manage payments separately outside the platform?

Accepted Answer

Platform-managed payment handling (including international tax/compliance complexity) removes real administrative burden; a platform that only tracks findings but leaves payment logistics to the customer is a materially thinner offering.

Question 4

How does the platform prevent and handle duplicate submissions and researcher disputes over severity/reward, and what is the appeals process if a researcher disagrees with a severity determination or reward amount?

Accepted Answer

A documented, fair dispute/appeals process matters for maintaining researcher trust and pool quality over time; a platform with no formal appeals process risks alienating good researchers who feel unfairly treated.

Question 5

Detail integration with the internal remediation workflow — do validated findings automatically create tracked tickets (Jira, etc.) with SLA tracking by severity, or does the customer need to manually re-enter findings into their own tracking system?

Accepted Answer

Automatic ticket creation with severity-based SLA tracking closes the loop from finding to fix; manual re-entry is both a friction point and a risk that findings get lost or delayed.

Question 6

What scope-management capability exists — can the customer precisely define in-scope/out-of-scope assets and have that scope automatically enforced (researchers can't submit against out-of-scope targets), or is scope purely a written policy researchers must self-police?

Accepted Answer

Technically enforced scope boundaries are stronger than a written policy relying on researcher self-discipline, which reduces out-of-scope testing risk for the customer.

Question 7

Explain how the platform supports compliance-driven vulnerability disclosure requirements (e.g., a documented VDP satisfying specific regulatory or customer-contractual requirements) and whether program activity/metrics are exportable as audit evidence.

Accepted Answer

Exportable program metrics and a documented VDP process are useful compliance evidence; ask for a specific example export rather than accepting a general 'compliance-ready' claim.

Question 8

What visibility does the customer have into overall researcher engagement and program health (submission volume trends, researcher retention, time-to-fix trends) as ongoing metrics, versus only seeing individual findings with no program-level analytics?

Accepted Answer

Program-level analytics help the customer judge whether the bounty program is actually working over time (declining engagement is a real signal); a platform offering only per-finding visibility with no trend data is a thinner offering.

Question 9

What is the pricing model — platform management fee plus researcher payouts, or an all-inclusive managed program — and what is the typical all-in annual cost for a program of comparable scope, including researcher rewards?

Accepted Answer

Look for transparent, all-in cost figures including both platform fees and typical reward spend, not just the platform's own management-fee headline price.

Question 10

Does a critical-severity finding automatically trigger a fast-track internal escalation distinct from the routine triage queue, and what is a customer-referenced example of a critical finding leading to same-day remediation coordination?

Accepted Answer

A critical vulnerability found by a researcher deserves the same urgency as one found any other way — ask for a specific fast-track escalation mechanism and a real customer example.

Question 11

Detail historical trend reporting on program ROI — cost-per-critical-finding compared to traditional penetration testing, and submission-quality trend over the program's lifetime — suitable for demonstrating program value to leadership.

Accepted Answer

A real ROI comparison against traditional pentest cost-per-finding is a meaningful, evaluable metric — ask for a specific customer-referenced figure, not a generic 'more cost-effective' claim.

Question 12

How does the platform integrate with the customer's existing vulnerability-management/ASPM tooling so validated bug-bounty findings feed into the same unified risk view rather than a disconnected bug-bounty-specific dashboard?

Accepted Answer

Look for genuine integration into a unified risk view; a standalone bug-bounty dashboard disconnected from the broader VM/ASPM picture creates real reconciliation burden.

Question 13

Who within the organization gets access to submitted findings before remediation, and is there a strict, documented access model given that a submitted report is effectively a live, exploitable vulnerability description until it's fixed?

Accepted Answer

An unremediated bug-bounty submission is an actively exploitable vulnerability description — ask for a specific, strict access-control model, not just generic RBAC, given the sensitivity of unpatched findings.

Question 14

How does the platform genuinely attract and retain high-quality researchers (not just raw researcher-count marketing) — what is the actual submission-quality distribution, and does the platform provide a meaningful reputation/leaderboard system that top researchers actually value?

Accepted Answer

Raw researcher-count is a weak signal — ask for submission-quality distribution data and evidence that the platform's reputation system genuinely attracts top talent, not just volume.

Question 15

What safe-harbor and legal-protection language does the platform provide for researchers testing in good faith, and has this language been tested/relied upon in a real dispute — a well-designed safe-harbor policy is important for attracting serious researchers who fear legal exposure.

Accepted Answer

Real, tested safe-harbor language (not just boilerplate) is an important researcher-attraction factor — ask for evidence this has actually mattered in practice, not just confirmation that a safe-harbor clause exists.

Question 16

Can the platform support running both a private (invite-only) program and a public program simultaneously for different scopes or maturity stages, and how are researchers and findings managed distinctly across the two?

Accepted Answer

Many organizations start with a private program before graduating to public — ask for a specific answer on running both concurrently with properly separated management, not just support for one model at a time.

Bug Bounty evaluation questionnaire

Build your evaluation

Match on your requirements

1. Weight what matters

2. Pick vendors to compare

Platform baseline

From other buyers